Apellis Pharmaceuticals Inc APLS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:35 PM EDT
47.17quote price arrow up+1.12 (+2.43%)
Volume
456,605
52 week range
19.83 - 94.75
Loading...
  • Open46.62
  • Day High47.74
  • Day Low46.10
  • Prev Close46.05
  • 52 Week High94.75
  • 52 Week High Date06/14/23
  • 52 Week Low19.83
  • 52 Week Low Date08/07/23

Key Stats

  • Market Cap5.688B
  • Shares Out120.58M
  • 10 Day Average Volume1.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.99
  • YTD % Change-21.11

KEY STATS

  • Open46.62
  • Day High47.74
  • Day Low46.10
  • Prev Close46.05
  • 52 Week High94.75
  • 52 Week High Date06/14/23
  • 52 Week Low19.83
  • 52 Week Low Date08/07/23
  • Market Cap5.688B
  • Shares Out120.58M
  • 10 Day Average Volume1.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.99
  • YTD % Change-21.11

RATIOS/PROFITABILITY

  • EPS (TTM)-4.48
  • P/E (TTM)-10.53
  • Fwd P/E (NTM)-38.29
  • EBITDA (TTM)-515.338M
  • ROE (TTM)-290.14%
  • Revenue (TTM)396.591M
  • Gross Margin (TTM)85.25%
  • Net Margin (TTM)-133.29%
  • Debt To Equity (MRQ)210.10%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Apellis Pharmaceuticals Inc

 

Profile

MORE
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of...
Gerald Chan
Independent Chairman of the Board
Cedric Francois M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Nur Nicholson
Chief Technical Operations Officer
Adam Townsend
Chief Operating Officer
Timothy Sullivan
Chief Financial Officer, Treasurer
James Chopas CPA
Chief Accounting Officer, Vice President, Corporate Controller
David Watson J.D.
General Counsel
Address
100 Fifth Avenue
Waltham, MA
02451
United States